These innovative molecules represent a significant advancement in the therapy of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in reducing blood glucose levels. https://gretausnh160252.worldblogged.com/45423575/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide